Technological offers - SATT NORD

Return

TIGER: Novel intestinal topical agonists of the TGR5 bile acids receptor for the treatment of the Type 2 diabetes and its metabolic complications

Description

Activation of TGR5 receptor is recognized for stimulating the secretion of incretin GLP1.
Increased secretion of GLP 1 is used as a treatment of type 2 diabetes thanks to GLP-like products (Victoza, Byetta)

Benefits:

  • Topical Molecules (very low systemic leakage)
  • POC in vivo for the secretion of endogenous GLP-1, improvement of insulin resistance, fasting glycemia and insulinemia, and weight lost in acute and chronic administration in diabetic mice model.
  • Orally active
  • No toxic effect, particularly on gallbladder

Sheet

Download the offer

 

Fields

Biology / Medical

Sectors

Health